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L E T T E RI N F LUENZAComment on “Antibodies to influenza nucleoprotein
cross-react with human hypocretin receptor 2”
Anne Vassalli,* Sha Li, Mehdi Tafti*
Did hypocretin receptor 2 autoantibodies cause narcolepsy with hypocretin deficiency in Pandemrix-vaccinated
children, as suggested by Ahmed et al.? Using newly developed mouse models to report and inactivate hypocretin
receptor expression, Vassalli et al. now show that hypocretin neurons (whose loss causes narcolepsy) do not express
hypocretin autoreceptors, raising questions to the interpretation of Ahmed et al.’s findings. o
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 Ahmed and colleagues (1) recently reported that “antibodies to influ-
enza nucleoprotein cross-react with human hypocretin receptor 2.”
This important finding might explain why many cases of child narco-
lepsy were reported after immunization with the Adjuvant System 03
(ASO3)–adjuvanted A(H1N1)pdm09 influenza vaccine (Pandemrix)
during the 2009 flu pandemia, mainly in Finland and Sweden where
the highest rates of vaccination were achieved in Europe. Besides sev-
eral concerns about the report of Ahmed and colleagues (1) [for example,
55% of control children were found positive for these autoantibodies
as well, lack of availability of peripheral cells and cerebrospinal fluid
(CSF), and no evidence of disease transfer in an animal model], a
major unanswered question is how these anti–hypocretin receptor 2
(HCRTR2) antibodies may cause the disease. A direct antibody-
dependent cell-mediated cytotoxicity appears unlikely as this would re-
sult in a massive damage and detectable inflammatory signs because
HCRTR2 is expressed in numerous brain cell types, including some with
critical functions (such as histaminergic and serotonergic cell groups)
(2). A plausible hypothesis might be (if it is shown that these anti-
bodies penetrate the brain) that, similar to myasthenia gravis, anti-
HCRTR2 antibodies block and inhibit HCRTR2 function. Such process
can lead to narcolepsy symptoms because spontaneousmutations in the
Hcrtr2 gene are found to cause narcolepsy in dogs (3), and mice in
which the Hcrtr2 gene was inactivated also present narcolepsy-like
symptoms (4). In humans, in contrast, both sporadic and, presumably,
post-H1N1 cases of narcolepsy with cataplexy are caused by the specific
loss of hypocretin (HCRT)–producing neurons. Postmortem examina-
tion of narcoleptic brains uncovered extensive loss of these neurons
together with the colocalized dynorphin and narp (neuronal activity–
regulated pentraxin) neuropeptides in the lateral hypothalamus (5, 6).
Also, deficiency in HCRT-1 in the CSF allows specific diagnosis of nar-
colepsy (7). One may hypothesize that HCRTR2 blockade by autoanti-
bodies inhibits HCRTproduction (HCRT neurons are intact but they do
not produce HCRT and colocalized neuropeptides), either by directly
binding HCRT neurons or by binding other neurons regulating them.
Binding and inhibition of HCRTR2may thus occur in HCRT-producing
neurons themselves. Indeed, Yamanaka and colleagues (8) usedHcrt
gene promoter-driven enhanced green fluorescent protein (eGFP)
transgenic mice and reported that hypocretin neurons are critically
and directly controlled by HCRTR2, thus arguing that hypocretin
neurons express HCRTR2 as autoreceptor. However, these transgenic
mice are thought to lack specificity, so not all eGFP-immunoreactive
neurons are HCRT-positive. Moreover, commercially available anti-Center for Integrative Genomics, University of Lausanne, CH-1015 Lausanne,
Switzerland.
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www.ScienceHCRTR2 antibodies [as used in the study of Ahmed and colleagues
(1)] lack reliability. HCRTR2 expression has thus been difficult to assess
at single-cell type resolution, and whether HCRT neurons express
HCRTR2 is controversial.
It is noteworthy that in both mouse and dog models of HCRTR2 de-
ficiency,HCRTneurons shownormal distribution andHCRTproduction,
and brain HCRT levels appear normal [(4, 9), and Fig. 1E for the mouse
model reported here]. Thus, themechanism by which lesions in HCRTR2
lead to narcolepsy with hypocretin deficiency remains unclear.
We have generated mouse conditional knockout (KO) alleles for
Hcrtr1 and Hcrtr2. Our conditional alleles are designed in a way that
when Cre-mediated excision within the gene occurs, GFP replaces the
endogenous protein encoding region (Fig. 1, A and B) and therefore can
be used as a reliable reporter for mapping of cells in which these recep-
tors are endogenously expressed (10). By using GFP and HCRT double
immunohistofluorescence, we found no HCRT/HCRTR2 double-
labeled neurons, strongly indicating that HCRT neurons lack HCRTR2
(Fig. 1E). In contrast, our mouse model clearly reveals HCRTR2 ex-
pression in histaminergic neurons of the tuberomammillary nucleus
(Fig. 1C). Nevertheless, many other hypothalamic (Fig. 1E) and extra-
hypothalamic cells are GFP-positive. The identity of many of these
HCRTR2 neurons is unknown, and whether they project to and even-
tually activate (or in any manner affect the activity of) HCRT neurons
needs further studies. We found that most hypocretin neurons (302 of
316) also do not express HCRTR1 (Fig. 1F). In conclusion, HCRT defi-
ciency in narcolepsy is most probably due to a specific destruction of
HCRT-producing neurons, and although the mechanism (presumably
autoimmune attack) remains unknown, there is no evidence that this
includes antibodies against HCRTR2. Therefore, until the pathogenicity
of the reported anti-HCRTR2 antibodies is established, the findings of
Ahmed and colleagues (1) should be considered as preliminary and
not as evidence for molecular mimicry between H1N1 nuclear protein
and HCRTR2, resulting in hypocretin deficiency.REFERENCES AND NOTES
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Fig. 1. The vast majority of mouse HCRT neurons express neither Hcrtr1
nor Hcrtr2 receptor genes. (A and B) Schematic representation of Hcrtr2 (A)
(TH, red) and anti-GFP (green) antibodies. (E and F) HCRT-immunoreactive
neurons (red) in the hypothalamus of a Hcrtr2D-GFP mouse (E), and mostand Hcrtr1 (B) targeting strategy used to generate the conditional KO
(“floxed”) alleles, and, after Neo excision and Cre-mediated recombination,
the D-GFP KO alleles (10). (C to F) Representative confocal micrographs of
coronal brain sections from Hcrtr2D-GFP (C and E), or Hcrtr1D-GFP (D and F)
mice stained by immunofluorescence. (C) Histamine neurons in the ventral
tuberomammillary nucleus (vTMN) of the hypothalamus of a Hcrtr2D-GFP
mouse are co-stained with anti–histidine decarboxylase (HDC, red) and anti-
GFP (green) antibodies. (D) Norepinephrine neurons in the locus coeruleus
(LC) of a Hcrtr1D-GFP mouse are co-stained with anti–tyrosine hydroxylasewww.ScienceHCRT-immunoreactive neurons in a Hcrtr1D-GFP mouse (F), are located in
proximity of, but are not themselves, GFP-immunoreactive cells (green), indi-
cating that they do not express HCRT receptors. (E) Depicts a homozygous
Hcrtr2D-GFP KO mouse, demonstrating normal HCRT production in absence
of functional HCRTR2 receptor. DMH, dorsomedial hypothalamus; fx, fornix;
LHA, lateral hypothalamic area; mtt, mammillothalamic tract; TSS,
transcription start site; VMH, ventromedial hypothalamus. Blue, DAPI-stained
nuclei. Arrowheads in (F) identify isolated HCRT/GFP doubly stained cells.
Scale bars, 100 mm [main image in (C) to (F)]; 50 mm [inset in (C) to (F)].TranslationalMedicine.org 18 November 2015 Vol 7 Issue 314 314le2 2
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